U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefepime and Enmetazobactam Injection
  1. Development Resources

Cefepime and Enmetazobactam Injection

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion b
(zone diameter in mm)

Pathogen

S

SDD

I

R

S

SDD

I

R

Enterobacterales a,c

≤8/8

-

-

≥16/8

≥21

-

-

≤20

Pseudomonas aeruginosa a

≤8/8

-

-

≥16/8

≥18

-

-

≤17

S = Susceptible; SDD= susceptible-dose dependent; I = Intermediate; R = Resistant

  1. Susceptibility interpretive criteria are based on a dose of 2 grams cefepime and 0.5 g enmetazobactam every 8 hours by intravenous infusion over 2 hours in patients with an estimated glomerular filtration rate from 60 mL/min to less than 130 mL/min.
  2. For disk diffusion, use paper disks impregnated with 30/20 mcg cefepime/enmetazobactam.
  3. Among Enterobacterales species, clinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae complex.
Back to Top